Cantor Shines Light on TherapeuticsMD Inc (TXMD) Following Publication of Clinical Data in Menopause
Cantor analyst William Tanner is out today with a few insights on TherapeuticsMD Inc (NYSEMKT:TXMD), after the drug maker announced the publication of a manuscript detailing results of the Women’s Health Initiative Observational Study of vaginal estrogen use in postmenopausal women in the journal Menopause.
Tanner commented, “We believe the probability of FDA approval of TX-004 for treating vulvar vaginal atrophy (VVA) is high and that it will become an important therapy with which to treat the condition. Publication of data in the journal Menopause supports the notion that low-dose vaginally delivered estrogen may not be unsafe as it relates to cardiovascular disease and cancer, in our view. Expected to be submitted to the FDA, we believe the study results, as detailed in the article, will support the approval of TX-004, most important because of the Agency’s comfort in not requiring 12- month endometrial safety-testing results prior to approval. The need to examine safety as a Phase 4 requirement would be burdensome, in our view, mainly as it relates to the cost because ob/gyn consultants with whom we speak are of the opinion that the risk is very low that a safety signal would be observed in a 12-month study.”
As such, Tanner reiterates an Overweight rating on shares of TherapeuticsMD, with a price target of $33, which represents a potential upside of 434% from where the stock is currently trading. (To watch Tanner’s track record, click here)
Overall, the 6 analysts polled by TipRanks in the past 5 months rate TherapeuticsMD stock a Buy. With a return potential of 214%, the stock’s consensus target price stands at $19.50.